TOP NEWS: Hikma confirms 2021 guidance amid strong performance
TOP NEWS: Hikma confirms 2021 guidance amid strong performance
Read moreWed, 17th Apr 2013 15:19
TOP NEWS: Hikma confirms 2021 guidance amid strong performance
Read more(Sharecast News) - Hikma Pharmaceuticals reiterated full-year guidance as the company reported solid trading across its business.
Read more(Sharecast News) - Analysts at Citi reiterated their 'buy' stance for shares of Hikma Pharmaceuticals ahead of the company's trading statement due out later in the same week.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreLONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco
Read moreLONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills
Read moreLONDON BROKER RATINGS: Upgrades for Ferrexpo, Go-Ahead and Old Mutual
Read more(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Rolls-Royce jumps on sales of Spain-based ITP, U.S. Air Force contract* Energy stocks track crude oil prices higher* Hikma Pharma gains o...
Read moreLONDON MARKET OPEN: Rolls-Royce rises on US Air Force contract win
Read moreTOP NEWS: Hikma buys US injectables firm Custopharm for USD375 million
Read moreLONDON MARKET PRE-OPEN: Rolls-Royce wins USD2.6 billion B-52 contract
Read more(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.
Read more(Sharecast News) - Hikma Pharmaceuticals said it was buying US firm Custopharm from Water Street Healthcare Partners for $375m on a debt and cash-free basis, with a further $50m payable on meeting certain commercial milestones.
Read moreLONDON BROKER RATINGS: JPMorgan downgrades Unilever and Coca-Cola HBC
Read more